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ment identiﬁed are necessarily the best available for the purpose.High levels of the expression of the human epidermal
growth factor receptor (HER)-2 protein, due to ampliﬁcation
of the HER2 gene (ERBB2), frequently occurs in breast
cancers1,2 and gastrointestinal cancers.3,4 The classic
methods of measurement of HER2 are immunohistochem-
istry analysis for protein expression and ﬂuorescence in situ
hybridization techniques for gene ampliﬁcation.5 The ac-
curate measurements of HER2 ampliﬁcation levels are
important for determining the proper treatment using anti-
HER2 therapeutics.4,6,7
There is a good correlation between the HER2 gene copy
numbers and HER2 protein expression using immunohis-
tochemistry analysis and ﬂuorescence in situ hybridization
methods when the measurements are carefully performed in
clinical breast cancer samples8 and also in breast cancer cell
lines.9 An analysis of individual cells from breast cancer cell
lines showed a good correlation between a high copy
number of chromosome 17 (where the HER2 gene is
located) and high HER2 protein expression.9merican Society for Investigative Pathology an
Y-NC-ND license (http://creativecommons.orgRecently, real-time quantitative PCR (qPCR) was shown
to be a sensitive method of conﬁrming HER2 gene ampli-
ﬁcation in clinical samples in which immunohistochemistry
analytical methods have failed.10 There is considerable in-
terest in measuring the ampliﬁcation of the HER2 gene
along with other gene targets in cancer, using quantitative
nucleic acid measurement techniques, especially thosed the Association for Molecular Pathology.
/licenses/by-nc-nd/4.0).
Lih et almethods that can screen for panels of mutations to tailor
treatments for individual patients.11
Next-generation sequencing (NGS) provides a powerful
tool to detect multiple genetic alterations in a quantitative
manner. Targeted-amplicon and whole-exome sequencing
(WES) technologies for mutation measurements in cancer
are becoming more widespread in clinical laboratories.
Those NGS assays sequence targeted regions with clinically
or biologically relevant genetic loci with high read depth
coverage. Therefore, the assay can achieve high sensitivity
for detecting somatic mutations in cancer. However, clini-
cally relevant copy number variations (CNVs) are an
essential measurement. NGS has shown great promise, and
advances in computation methods have occurred,12e14 but
these methods have not yet been fully validated using
reference materials to conﬁrm the calculations. Recently, the
use of whole-genome sequencing (WGS) (at low coverage
levels), along with recent advances in computation methods,
has allowed for the calculation of CNVs using NGS.13
Guidelines on the quality management of NGS in clinical
applications have been proposed, including test validation,
quality-control procedures, proﬁciency testing, and the use
of reference materials.15 NGS assays intended for clinical
oncology applications have been validated using pooled
cancer cell lines and clinical samples.16,17
Reference materials are well-characterized samples that are
ensured to be homogenous and stable and to accurately reﬂect
the intended analyte. They can be used to ensure that mea-
surement methods are working correctly, to calibrate in-
struments, to evaluate assay performance, to identify the
weaknesses of the measurement process, and to assign values
to other materials.18 Reference materials are used to improve
the conﬁdence and reliability of measurement methods by
providing samples that are ensured to have the certiﬁed
properties for their intended purpose. There are signiﬁcant
challenges in producing reference materials from biological
materials, especially cell lines that require a high level of
characterization, because of differences in the genomic ma-
terials due to the genetic drift that occurs during cell culture.
Currently, reference materials for cancer measurements are
very limited. A World Health Organization international
standard for the BCR-ABL mRNA levels consists of mixtures
of cell lines to obtain different levels of the gene fusion
mRNA target.19 The Genetic Testing Reference Materials
coordination program (Centers for Disease Control and
Prevention, http://www.cdc.gov/clia/Resources/GetRM, last
accessed July 8, 2016) publishes consensus data from inter-
laboratory measurements on cell lines obtained from cell
repositories.20e22 Due to the lack of referencematerials, many
laboratories produce their own control materials derived from
cell lines or limited patient samples on an ad hoc basis.
However, these ad hoc materials are not characterized fully,
and stability and homogeneity may not have been determined.
In this report, we show the utility of the National Institute
of Standards and Technology’s (NIST) Standard Reference
Materials (SRM) 2373 to ensure the quality and improve the754conﬁdence of the measurement of HER2 gene ampliﬁcation
using different NGS methods.
Materials and Methods
Preparation of Cell Lines
Details regarding the certiﬁcation of NIST SRM 2373 are
available from the certiﬁcate of analysis and an article
describing the development and characterization of SRM
2373.23 The cell lines were obtained from the American
Type Culture Collection (ATCC) (Manassas, VA) and
grown in the NIST laboratories using the recommended
culture conditions. The breast cancer cell lines have
different sources, hormone sensitivity,24 and
karyotypes25e28 (Table 1). The HapMap cell lines CEPH
NA12878 (characterized by the Genome in The Bottle
consortium29), Chinese Female (NA18526), and Yoruban
(NA18507) were used as reference genomes for the NGS
methods. All three HapMap cell lines were obtained from
the Coriell Institute for Medical Research (Camden, NJ) and
cultured using the recommended culture conditions.
DNA Extraction, Identity Authentication, and
Reference Material Preparation
Genomic DNA samples were prepared using the Quick-
gDNA MidiPrep kit (catalog number D3100; Zymo
Research, Irvine, CA). The DNA samples were treated with
bovine pancreatic ribonuclease A before puriﬁcation to
remove the enzyme.23 All puriﬁed genomic DNA samples
were prepared in buffer (10 mmol/L Tris, 0.1 mmol/L EDTA,
pH 8.0) and stored at 4C. The cell line DNA was authenti-
cated using the AmpFLSTR Identiﬁler Plus PCR Ampliﬁ-
cation Kit (catalog number 4427368; Life Technologies,
Carlsbad, CA) on a 3500xl Genetic Analyzer with a 36-cm
capillary array and POP-4 polymer (Life Technologies).
The DNA samples were analyzed both when received from
the repository and when the cells were expanded to produce
the genomic DNA used for the production of SRM 2373.23
The short tandem repeat markers matched the values docu-
mented by ATCC. Cell lines were checked for myoplasma
contamination using a PCR kit (Universal Mycoplasma
Detection Kit 30-1012K; ATCC). An approximate concen-
tration of the DNA components was determined using
absorbance at 260 nm on ﬁve replicates (using the value 1
absorbance unit at 260 nmZ 50 mg/mL).23
qPCR and dPCR at NIST
TaqMan assays for HER2 and the four reference genes were
developed at NIST23 and validated using the MIME30 and
dMIME31 guidelines. The primers and gene locations are
shown in Table 2, and the probes, in Table 3. Black hole
quencher 1e and ﬂuorescein amiditeelabeled probes were
obtained from LGC Biosearch Technologies (Novato, CA).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Information for the Five Cell Lines Used in SRM 2373
Cell line
MDA-MB-231
component B
MDA-MB-361
component C
MDA-MB-453
component D BT474 component E
SK-BR-3
component A
Source Pleural effusion Brain metastasis Pericardial effusion Invasive ductal
carcinoma
Pleural effusion
metastasis
Karyotype Hypotriploid26 Hyperdiploid25 Tetraploid27,28 Hypertriploid25 Hypertriploid25
(highly modiﬁed)
Type Basal24 Luminal A24 Luminal24 Luminal A24 Luminal B24
Hormone status Triple negative24 ER positive24 Negative ER/PR24 Triple Positive24 Negative ER24
NIST-certiﬁed ratio 1.3 6.4 2.9 17.7 9.7
95% uncertainty
interval
1.1e1.5 5.7e7.1 2.6e3.2 15.9e19.5 8.7e10.7
ER, estrogen receptor status; NIST, National Institute of Standards and Technology; PR, progesterone status; SRM, Standard Reference Material.
HER2 Reference Materials for NGSThe qPCR measurements were taken using SYBR Green to
determine the quantitation cycle using the ABI 7500 PCR
System (Life Technologies). A quantitative human genomic
DNA standard, SRM 2372 component A (produced from
white blood cells from a healthy human male donor), was
used to calibrate the standard curves for HER2 and the
reference genes.23 The chamber dPCR reactions were run on
a BioMark platform (Fluidigm, San Francisco, CA) and the
droplet dPCR assays were performed using a Q100
Droplet Digital PCR System (Bio-Rad, Hercules, CA).
dPCR at MoCha
The SRM2373 material was further characterized by digital
PCR (dPCR) at the Molecular Characterization and Clinical
Assay Development Laboratory (MoCha), Frederick Na-
tional Laboratory for Cancer Research (Frederick, MD). The
dPCR assays used the PCR primers and TaqMan probes
shown in Tables 2 and 3. The dPCR assays at MoCha were
performed using a QX200 Droplet Digital PCR System
(Bio-Rad). NIST SRM 2373 components A to E and CEPH
NA12878 DNA samples were diluted to approximately 5
ng/mL using PCR-grade water. Additionally, components A
and E DNA samples were diluted to 1 ng/mL using PCR-
grade water. dPCR reactions (25 mL) were prepared in
triplicate for each DNA sample/gene combination. TheTable 2 PCR Primer Information for Reference Genes and HER2 Assay
Primer
name Sequence
PCR ampl
(bp)
HER2-2F 50-CTCATCGCTCACAACCAAGT-30 112
HER2-2R 50-GGTCTCCATTGTCTAGCACG-30
EIF5-F 50-GGCCGATAAATTTTTGGAAATG-30 112
EIF5-R 50-GGAGTATCCCCAAAGGCATCT-30
2PR4-F 50-CGGGTTTGGGTTCAGGTCTT-30 97
2PR4-R 50-TGCTACAATGAAAACATTCAGAAGTCT-30
R4Q5-F 50-CTCAGAAAAATGGTGGGAATGTT-30 122
R4Q5-R 50-GCCATTCAGAGAGGCAAGCT-30
22C3-F 50-AGGTCTGGTGGCTTCTCCAAT-30 78
22C3-R 50-CCCCTAAGAGGTCTGTTGTGTTG-30
MoCha, Molecular Characterization and Clinical Assay Development Laboratory
The Journal of Molecular Diagnostics - jmd.amjpathol.orgdPCR reactions consisted of 2 dPCR Supermix for Probes
(no 20-deoxyuridine 50-triphosphate) (Bio-Rad), 900 nmol/L
ﬁnal concentration forward and reverse primers, 250 nmol/L
probe, and 4 mL of the prepared DNA dilutions. DNA
templates (20 ng) were loaded for all reactions except HER2
detection of components A and E. For these reactions, 4 ng
of DNA was loaded, due to high levels of HER2 ampliﬁ-
cation. The dPCR reaction plates were placed on an Auto-
mated Droplet Generator (Bio-Rad) on which droplets were
generated and then transferred to a 96-well PCR plate. The
plate was heat-sealed with a foil seal and placed on a C1000
Touch Thermal Cycler (Bio-Rad). Ampliﬁcation was per-
formed as follows: 95C for 10 minutes, 40 cycles at 94C
for 30 seconds, 60C for 60 seconds, 98C for 10 minutes,
and 4C hold. On completion of ampliﬁcation, droplets
were analyzed on a QX200 Droplet Reader (Bio-Rad) using
the Abs experiment setting. Data were analyzed using
QuantaSoft software version 1.7.4.0917 (Bio-Rad). The
number of copies per microliter from each sample was
divided by the total dilution factor (0.04 for reactions with
20 ng input, 0.008 for reactions with 4 ng total input) to
yield the copies per microliter for each stock sample.
Measurements of each gene were performed on triplicate
samples for each component of SRM 2373. The ratios of
HER2 to the reference genes were calculated by dividing the
overall mean of the copy numbers from the four references Used by MoCha
icon
Gene name
Location (GRCh37/hq19 nucleotide
number)
HER2 (17q12) Exon 7 (chr17:37864601-37864620)
(chr17:37864693-37864712)
EIF5B 2q11.2 Intron 1 (chr2:99974140-99974161)
(chr2:99974231-99974251)
RPS27A 2p16 Intron 4 (chr2:55462316-55462335)
(chr2:55462386-55462412)
DCK 4q13.3-q21.1 Exon 3 (chr4:71888097-71888119)
(chr4:71888199-71888218)
PMM1 22q13.2 Intron 7 (chr22:41973739-41973759)
(chr22:41973682-41973704)
at the Frederick National Laboratory for Cancer Research (Frederick, MD).
755
Table 3 TaqMan Fluorescent Probe Sequences for HER2 and Reference Gene Assays Used by MoCha
Probe name Sequence 50 Label 30 Quencher
HER2-2 (BHQ) 50-ACCCAGCTCTTTGAGGACAACTATGC-30 FAM BHQ-1
EIF5-P 50-TTCAGCCTTCTCTTCTCATGCAGTTGTCAG-30 FAM BHQ-1
2PR4-P 50-TTTGTCTACCACTTGCAAAGCTGGCCTTT-30 FAM BHQ-1
R4Q5-P 50-CCTTCCAAACATATGCCTGTCTCAGTCGA-30 FAM BHQ-1
22C3-P 50-CAAATCACCTGAGGTCAAGGCCAGAACA-30 FAM BHQ-1
BHQ, black hole quencher; FAM, ﬂuorescein amidite; MoCha, Molecular Characterization and Clinical Assay Development Laboratory at the Frederick National
Laboratory for Cancer Research (Frederick, MD).
Lih et algenes into the individual HER2 assay copy number mea-
surements for each sample. All of the ratios were multiplied
by 2, for comparison to the normal diploid copy number in
normal cells.
NGS Assays
Three different NGS-based assays were used to characterize
the SRM 2373 materials at the MoCha laboratory.
Exome Sequencing
For each sample, a total of 500 ng of genomic DNA,
quantiﬁed by Qubit (Thermo Fisher Scientiﬁc, Waltham,
MA), was sheared to 150 to 200 bp by Covaris E220 son-
ication (Covaris, Woburn, MA). After cleanup with
AMPure XP beads (Beckman Coulter, Brea, CA), samples
were checked for correct size distribution using the 2100
Bioanalyzer system (Agilent Technologies, Santa Clara,
CA). Fragmented genomic DNA samples were processed
with end-repair, dA addition, ligation of sequencing adap-
tors, and two rounds of six-cycle preampliﬁcation using the
SureSelectXT Target Enrichment System (Agilent Tech-
nologies) for the Illumina Paired-End Sequencing Library
construction kit (Illumina, San Diego, CA). A total of 500
ng of ampliﬁed DNA was hybridized with a biotinylated
RNA bait set (SureSelectXT Human All Exon V5; Agilent
Technologies) at 65C for 24 hours. The captured genomic
DNA fragments were enriched by Dynal MyOne Strepta-
vidin T1 beads (Thermo Fisher) and ampliﬁed with bar-
coded index-attached primers for 12 cycles. The AMPure
XPepuriﬁed libraries were checked for size distribution
(300 to 400 bp) using an Agilent Bioanalyzer (Agilent
Technologies) and quantiﬁed using a Library Quantiﬁcation
Kit (Kapa Biosystems, Wilmington, MA). A pooled library
made by two ﬁnal libraries mixed at equal molar ratio was
clustered at 20 pM per ﬂowcell lane using the Illumina cBot
system before sequencing on an Illumina HiSeq 2500
platform (Illumina). Sequencing reactions were run using
2  125 paired-end mode. Demultiplexed FASTQ ﬁles were
generated with Casava software version 1.8.2 conﬁguration
bcl2fastq.pl (Illumina) from the .bcl ﬁles. The multiple
FASTQ ﬁles generated by this script were concatenated and
primer-trimmed using the ea-utils fastq-mcf tool with the
options “el 30 eq 10 eu eP 33” to remove Illumina PCR756and sequencing primers from the sequences. The trimmed
sequences were mapped to human genome reference hg19
using the Burrows-Wheeler Aligner software version 0.6.2
aln32 and sample mode in default settings. The resulting SAM
ﬁles were converted toBAMformat, sorted, de-duplicated, and
indexed using SAMtools and Picard.33 Three algo-
rithmsdcn.MOPS,34 CONTRA,35 and ExomeCNV36dwere
applied on the exome data to detect the CNVs. In brief,
cn.MOPS uses local modeling of the depth of coverage to
minimize false-positive CNV calling; similarly, CONTRA
uses base-level log-ratio of coverage between tumor and con-
trol to infer the gain or loss of each region. ExomeCNV is
based on data observed from six human samples captured
using a single-exome capture platform, and involved the
modeling of log-ratios using the Geary-Hinkley trans-
formation, forwhich a normally distributed exon-level depth of
coverage is assumed. Seven replicates of WES data generated
from HapMap CEPH 12878 were used as a reference to call
CNVs in SRM 2373 cell lines.Whole-Genome Sequencing
One microgram of DNA from each sample was used for
library preparation for WGS. The TruSeq DNA PCR-Free
Library Preparation Kit (catalog number FC-121-3001;
Illumina) was used for sequencing library preparation ac-
cording to the vendor’s recommended method (TruSeq Li-
brary Prep guide; Illumina). Sequencing libraries were
quantiﬁed using a Library Quantiﬁcation Kit (Kapa Bio-
systems). Subsequently, sequencing libraries from three
samples were pooled at equal molar ratios and requantiﬁed
using the same Library Quantiﬁcation Kit and were clus-
tered at 20 pM per ﬂowcell lane using the Illumina cBot
before sequencing on an Illumina HiSeq 2500 platform
(Illumina). A total of four replicates of WGS assay were
performed for each SRM cell line in two batches: One
replicate was performed in the ﬁrst batch, and other (total of
four) replicates were performed in the second batch.
Sequencing reactions were run using 2  125 paired-end
mode. FASTQ data generated using the bcl2fastq tool
version 1.84 (Illumina) were run through FastQC (Babra-
ham Bioinformatics, Cambridge, UK) for quality checking,
and any adaptor contamination and low-quality bases found
in reads were removed later by Trimmomatic.37 The pro-
cessed reads were mapped to the human hg19 referencejmd.amjpathol.org - The Journal of Molecular Diagnostics
HER2 Reference Materials for NGSgenome using NovoAlignMPI (default parameters; Novo-
craft Technologies, Selangor, Malaysia) on Biowulf cluster
(CIT/NIH). The resulting BAM ﬁles were sorted and
indexed using Picard.2 CNVnator38 was then applied on
these WGS data to detect copy number changes. This al-
gorithm uses the established mean-shift approach,39 with
additional corrections for multiple-bandwidth partitioning
and GC correction for more accurate CNV detection. For the
given HER2 gene, CNVnator was used to calculate the copy
number of the whole length of the gene by normalizing the
local read depth signal to the genomic average for the region
of the same length.dPCR (PMM1, RPS27A, DCK, EIF5B reference genes)
dPCR (RPS27A, DCK, EIF5B reference genes)
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Figure 1 Correlation of the droplet digital PCR measurements of Stan-
dard Reference Material 2373 components by the Molecular Characterization
and Clinical Assay Development Laboratory (Frederick National LaboratoryOncomine Targeted-Amplicon Sequencing Assay
The Oncomine Cancer Panel NGS assay40 (Thermo Fisher)
was used to determine the HER2 copy number. Two PCR
reactions each using 10 ng of DNA were prepared, one for
each primer pool in the Oncomine Cancer Research Panel,
using the Ion AmpliSeq Library Kit version 2.0 (Thermo
Fisher). The primer pools were combined after ampliﬁcation
and treated with FuPa reagent, and a separate Ion Xpress
barcode (Thermo Fisher) was ligated to each sample library.
The resulting libraries were puriﬁed and then quantiﬁed using
the Ion Library Quantitation Kit (Thermo Fisher). The Ion
PGM Template OT2 200 Kit and Ion OneTouch 2 System
(Thermo Fisher) were used to prepare templates for DNA
libraries, followed by enrichment on the Ion OneTouch ES.
The Ion Sequencing 200 Kit version 2, Ion 318 Chip Kit
version 2, and Ion Torrent PGM System (Thermo Fisher)
were used to sequence the template libraries. All procedures
were performed following the manufacturer’s instructions.
Completed runs were reviewed for quality based on thresh-
olds for the number of reads (3 million), read length (75
bp), uniformity (80%), 100 amplicon coverage (90%),
and median absolute pairwise difference values (<0.9). The
uniformity and amplicon coverage were determined using the
Coverage Analysis plug-in (Thermo Fisher). Data analysis
was performed using Torrent Suite software version 4.4.2 and
Ion Reporter software version 4.4.2 (Thermo Fisher). Copy
number analysis was performed using the Copy Number
module within the Oncomine Cancer Research Panel work-
ﬂow within the Ion Reporter system. To generate a baseline
for CNV calling, nine replicates of previously generated
Oncomine Cancer Panel HapMap normal values (3 CEPH
NA12878, 3 Chinese Female NA18526, and 3 Yoruban
NA18507) were imported onto the Ion Reporter server, and
the Copy Number Baseline module was run.for Cancer Research, Frederick, MD) with the National Institute of Standards
and Technology (NIST)-certiﬁed values. The NIST-certiﬁed ratios and 95%
CIs (horizontal bars) values (plotted on the x axis) were multiplied by 2. The
digital PCR (dPCR) experimental values (plotted on the y axis) for the ﬁve
NIST components were performed in triplicate for HER2 and the four refer-
ence genes. The dPCR copy number results were calculated by dividing the
mean dPCR values from either four reference genes (PMM1, RPS27A, DCK, and
EIF5B) or three reference genes (RPS27A, DCK, and EIF5B s) into the indi-
vidual HER2 copy number values.Results
The HER2 reference material is composed of genomic DNA
extracted from these well-characterized cell lines: SK-BR-3
(component A), MDA-MB-231 (component B), MDA-MB-
361 (component C), MDA-MB-453 (component D), andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgBT-474 (component E) (Table 1). The cell line used for
component B is classiﬁed as HER2 ampliﬁcationenegative,
and the other cell lines have moderate to high levels of
HER2 gene ampliﬁcation.
To test cross-laboratory performance, the NIST dPCR
assay methods and reagents were transferred to the MoCha
laboratory. The NIST dPCR assays were performed there
using different instruments and operators. Figure 1 shows
the correlation of the MoCha values to the NIST-certiﬁed
values. Brieﬂy, dPCR was used to measure HER2 and the
four reference genes for each of the samples; individual
assays for each sample were performed in triplicate. The
ratios were calculated by dividing the combined mean copy
numbers of either all four reference genes (PMM1, RPS27A,
DCK, and EIF5B) or of three reference genes (RPS27A,
DCK, and EIF5B) into the individual HER2 copy numbers
for each component. The exclusion of PMM1 improved the
correlation of component D, because the PMM1 dPCR
values for that component were approximately 70% higher
compared to the other reference genes. The presumptive
ampliﬁcation of PMM1 in component D was conﬁrmed by757
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Waltham, MA) targeted panel amplicons, the
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CNVnator38); whole-exome sequencing (WES) data
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cn.MOPS). Data are expressed as means  SD. nZ
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Lih et althe NGS data. Overall, the dPCR copy numbers showed
excellent agreement with the NIST-certiﬁed values
(Figure 1). The NIST-certiﬁed values were calculated using
three reference genes, of which the reference gene PMM1
was used for qPCR measurements of components B and C
only.23
Because the intended use of reference materials is to
improve conﬁdence and reliability in measurements, we
analyzed the reference materials on several different NGS
platforms. Figure 2 shows the results of using different
sequencing methods to measure copy numbers. Figure 2A
shows the gene map of HER2 along with the locations of the
dPCR amplicon (used in this study), the targeted amplicons
used in the Oncomine Cancer Panel, and the target regions
of probes used for WES. WGS assesses the entire HER2
gene, unlike the other methods, which interrogate only a
portion of the gene.
Figure 2B shows the comparison of three NGS methods
with the NIST-certiﬁed values. We observe that the HER2
copy numbers called by these NGS methods roughly align
with the certiﬁed values in the range of low to moderate
ampliﬁcations. Reproducibility was observed among mul-
tiple replicates within each of three NGS methods of
sequencing (amplicon, WES, and WGS). The HER2 copy
numbers determined from WES data by the three CNV758calling algorithms were comparable, but showed some dif-
ferences. Interestingly, all NGS methods underestimated the
high ampliﬁcation level in component E (copy number
>30). Copy number measured by targeted-amplicon
sequencing and WES methods seem to reach the plateau
at a HER2 copy number of 20, whereas the WGS
sequencing method shows a wider dynamic range.
The copy numbers of four reference genes measured
by WES and WGS (Figure 3) aligned well with dPCR re-
sults too. However, the data indicated that the reference
gene PMM1 appeared to be slightly ampliﬁed (approxi-
mately 50%) in component D, as shown on WGS and
WES sequencing (for copy numbers calculated by the
CONTRA and Exome algorithms, but not by the cn.MOPS
algorithm).Discussion
Certiﬁed reference materials are intended to provide a
source of uniform and stable samples that can be used to
calibrate measurement techniques to ensure that accurate
results are being obtained. It is important to ensure accurate
results to allow for the comparison of results from differentjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 3 Comparison of the four reference genes for each component, calculated by next-generation sequencingebased methods. AeC: Experimental values
for whole-exome sequencing (WES) data, calculated using either the cn.MOPS algorithm32 (A), the CONTRA algorithm33 (B), or the ExomeCNV algorithm34 (C).
D: Reference genes for the whole-genome sequencing (WGS) data were calculated using CNVnator.36 Data are expressed as means  SD. nZ 3 (AeC); nZ 4 (D).
HER2 Reference Materials for NGSmethods, instruments, laboratories, and operators, as well as
to ensure consistent measurements over time.
The NIST-certiﬁed values of the ratios of HER2 to the
different reference genes were established by extensive
measurements using qPCR and dPCR to determine the
reference values and measurement conﬁdence values. Multi-
ple instruments, PCR assays, operators, and experiments were
used to evaluate the conﬁdence of the certiﬁed values. PCR
assays were designed for different regions of HER2 (chro-
mosome 17) and the four reference genes (located on chro-
mosomes 2, 4, and 22).23 Assays were developed for the four
reference genes, RP27A, DCK, EIF5B, and PMM1, with
chromosomal locations of 2p11.2, 4q13.3e21.1, 2q11.2, and
22q13.2, respectively (Table 2)dlocations that were not
frequently found to exhibit CNVs in breast cancers, based on
literature studies.24,25,41 NIST SRM 2372 component A
(quantitative DNA reference material from a single male
donor) was used to calibrate the qPCR measurements to
determine the gene copy number of HER2 and the selected
reference genes. NIST SRM 2372 component A and CEPH
12878 were used to conﬁrm the dPCR measurements at the
MoCha laboratory.The Journal of Molecular Diagnostics - jmd.amjpathol.orgOur results support the importance of validating mea-
surement methods and using multiple reference genes and
not depending on only one reference gene. We evaluated
several commercial reference genes and found them to be
ampliﬁed in several of the components, as illustrated by the
slight ampliﬁcation of PMM1 in component D. The NIST-
certiﬁed values were based on the use of three reference
genes in the qPCR and dPCR measurements, and PMM1
was used for the component D calculations.23
With regard to reproducibility among the replicates of the
dPCR, three NGS methods indicated good precision for
each of these methods (Figure 2B). Comparison of three
different CNV-calling algorithms using the same WES data
also yielded similar HER2 copy number results. Similar
bioinformatics efforts have been applied to WGS CNV-
calling algorithms, such as RDXplorer,42 Wave CNV,43
CNV-seq,44 and ReadDepth.45 However, when we tried
these alternate algorithms for our WGS data, no fruitful
results were obtained due to the technical difﬁculties (ie, too
long of a run time, missing dependencies) or the challenges
of low coverage in these data sets. Given the fact that
CNVnator was chosen in a large-scale study (ie, 1000759
Lih et alGenomes46), our experience supports that CNVnator is
suitable for CNV detection using low-coverage WGS data.
Not surprisingly, each method demonstrated slightly
different HER2 copy numbers, likely associated with
platform-speciﬁc biases. Whole-exome data have been re-
ported to be somewhat challenging for accurately measuring
gene copy numbers,14 whereas WGS has been claimed to be
a better method for copy number measurement even at low
sequence coverage.13 Our results support that low-coverage
(5 in this case) WGS has a wider dynamic range than do
target-amplicon sequencing and WES for CNV detection.
The deviations in the HER2 ampliﬁcation results from NGS
methods may have been affected by the difference in the
locations of the interrogated regions (Figure 2A), the
chemistry (eg, capture efﬁciency in WES and primer-
annealing efﬁciency in target-amplicon sequencing), and
the choice of data analysis pipelines.
The absolute copy number measurement using target-
amplicon sequencing may not be accurate if the copy
number of HER2 is >20. However, the copy number
detection by target-amplicon sequencing shows very good
accuracy, with certiﬁed values when the copy number was
<20 (Figure 2B). The NCI-MATCH trial used the exact
same target-amplicon sequencing assay, and the threshold
copy number was set at 7, which is well within the accurate
range as the threshold for drug treatment (patients with a
copy number of 7 or above will be treated) (Lih CJ, Har-
rington RD, Sims DJ, et al., unpublished data). This notion
indicates that a wider dynamic may not be the most essential
concern with clinical assays; however, it is important to
determine whether the performance of the assay meets the
intended application.
These results clearly demonstrate the value of reference
materials for calibrations to permit a uniform basis for
comparing different methods. SRM 2373 provides such a
uniform and well-characterized set of genomic samples to
increase the conﬁdence in HER2 ampliﬁcation measure-
ments and analytical techniques. We are in the process of
developing additional reference materials for important
copy number mutations for cancer measurements.Acknowledgments
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